Identification of a novel mutation of FGFR3 gene in a large Chinese pedigree with hypochondroplasia by next-generation sequencing

A case report and brief literature review

Guixiang Yao, BS¹,², Guangxin Wang, MD, PhD¹, Dawei Wang, MS³, Guohai Su, MD, PhD¹,∗

Abstract

Rationale: Hypochondroplasia (HCH) is the mildest form of chondrodysplasia characterized by disproportionate short stature, short extremities, and variable lumbar lordosis. It is caused by mutations in fibroblast growth factor receptor 3 (FGFR3) gene. Up to date, at least thirty mutations of FGFR3 gene have been found to be related to HCH. However, mutational screening of the FGFR3 gene is still far from completeness. Identification of more mutations is particularly important in diagnosis of HCH and will gain more insights into the molecular basis for the pathogenesis of HCH.

Patient concerns: A large Chinese family consisting of 53 affected individuals with HCH phenotypes was examined.

Diagnoses: A novel missense mutation, c.1052C>T, in FGFR3 gene was identified in a large Chinese family with HCH. On the basis of this finding and clinical manifestations, the final diagnosis of HCH was made.

Interventions: Next-generation sequencing (NGS) of DNA samples was performed to detect the mutation in the chondrodysplasia-related genes on the proband and her parents, which was confirmed by Sanger sequencing in the proband and most of the other living affected family members.

Outcomes: A novel missense mutation, c.1052C>T, in the extracellular, ligand-binding domain of FGFR3 was identified in a large Chinese family with HCH. This heterozygous mutation results in substitution of serine for phenylalanine at amino acid 351 (p.S351F) and co-segregates with the phenotype in this family. Molecular docking analysis reveals that this unique FGFR3 mutation results in an enhancement of ligand-binding affinity between FGFR3 and its main ligand, fibroblast growth factor 9.

Lessons: This novel mutation is the first mutation displaying an increase in ligand-binding affinity, therefore it may serve as a model to investigate ligand-dependent activity of FGF-FGFR complex. Our data also expanded the mutation spectrum of FGFR3 gene and facilitated clinical diagnosis and genetic counseling for this family with HCH.

Abbreviations: ACH = achondroplasia, FGFR3 = fibroblast growth factor receptor 3, FGFs = fibroblast growth factors, HCH = hypochondroplasia, NGS = next-generation sequencing.

Keywords: c.1052C>T, FGFR3 gene, hypochondroplasia, next-generation sequencing

1. Introduction

Hypochondroplasia (HCH, MIM #146000) is the mildest form of fibroblast growth factor receptor 3 (FGFR3) chondrodysplasia with an incidence of about 1 in 50,000.[1,2] It is inherited in an autosomal dominant manner. HCH has a broader spectrum of phenotypes that occasionally overlap with those patients with achondroplasia (ACH, MIM #100800), another type of skeletal dysplasia with short-limbed dwarfism, and normal individuals of short stature.[3,4] Its clinical and radiographical features include disproportionate short stature, rhizomelic shortening of the extremities, short fingers, macrocephaly, flared metaphyses, variable lumbar lordosis, progressive narrowing of interpediculate distance in the lumbar vertebrate, short and squared ilia, and shortened tubular bones and short femoral necks.[5,6] Lack of trident hand, normal facies, and increased head circumference usually help distinguishing HCH from ACH.[7-9]

HCH is caused by mutations in FGFR3 gene which maps to chromosome 4p16.3. This gene belongs to the tyrosine kinase receptor family that includes 4 known members (FGFR 1–4). FGFR3 is composed of 1 extracellular, ligand-binding domain including 3 immunoglobulin-like loops (Ig I–III), 1 hydrophobic transmembrane (TM) domain, and 2 cytoplasmic TK subdomains TK1 and TK2 that are responsible for the catalytic activity.[10] It is expressed during skeletal growth and endochondral ossification and plays an important role in the regulation,
proliferation, differentiation, as well as other processes involved in growth and development.[11] Up to date, at least 30 mutations have been reported to be related to HCH according to the Human Gene Mutation Database (HGMD, http://www.hgmd.org/), Pubmed, Embase, and Web of science. However, mutational screening of the FGFR3 gene is still far from completeness. Identifying more novel mutations will gain more insights into the molecular basis for the pathogenesis of HCH.

With the development of new sequence technology, next-generation sequencing (NGS) has recently been used as an alternative approach to more traditional methods in the clinical practice including genetic diagnosis, family genetics counseling, and prenatal diagnostic testing.[12] NGS has many advantages which can not only produce massive amounts of data in parallel but also to measure each base pair to an unprecedented depth, which greatly reduces the time and cost of sequencing each sample at each locus.[13]

In this study, we described the clinical and radiographical manifestations of a large Chinese Han family with 53 affected individuals by HCH. Then, we used an approach based on targeted gene capture and NGS in this family and identified a novel missense mutation, c.1052C>T (S351F), in the extracellular, ligand-binding domain of FGFR3, which is outside the common mutation hot spot of this condition. Furthermore, in silico analysis was performed on this gain of function mutation. Identification of this novel mutation provides new insights into the molecular basis for the pathogenesis of HCH and assists early diagnosis.

2. Patients and methods

2.1. Proband and family investigation

The pedigree is shown in Figure 1. The proband (VI-5) was a 7-year and 8-month-old Chinese Han girl, who was born at full term after an uncomplicated pregnancy and delivery. At birth, she weighed 3.1 kg and her length was 50.5 cm. She was referred to hospital because of her short stature. The proband has not received any treatment up to the present.

The family history investigation shows that there were 52 other affected individuals in this Chinese Han family. All available individuals with a positive history underwent a full physical examination, including height, intelligence, and head circumference. Some family members had skeletal X-rays.

This study was approved by the research ethics committee of Jinan Central Hospital Affiliated to Shandong University. Informed consents were obtained from all subjects or their legal guardians. The parents of proband have provided informed consent for publication of the case.

2.2. Methods

2.2.1. Targeted sequence capture and NGS. NGS was performed on the proband and her parents (VI-5; V-17; V-18).

2mL of peripheral blood were collected and then preserved in anticoagulation tubes. Genomic DNA was isolated from peripheral whole blood using TIANamp Blood DNA Kit (Tiangen Biotech Beijing Co. LTD., China). After the DNA extraction, target sequences were enriched by using customized capture probes chips (Illumina, San Diego, CA), which included 10 genes (FGFR3, COMP, BMPR1B, ARSE, AGPS, ACP5, GDF5, COL2A1, TRIP11, and SLC26A2 gene) that are associated with chondrodysplasia. DNA probes were designed for exons and flanking intron sequences (~20 base pairs). 1μg
genomic DNA was fragmented into 200 to 300 bp length by Covaris Acoustic System. The DNA fragments were then processed by end-repairing, A-tailing and adaptor ligation, a 4-cycle pre-capture PCR amplification, targeted sequences capture. Captured DNA fragments were eluted and amplified by 1.5 cycle post-capture PCR. The final products were sequenced with 150-bp paired-end reads on Illumina HiSeq X Ten platform according to the standard manual.

The clean short-reads were mapped to human genome (hg19) using BWA software (http://sourceforge.net/projects/bio-bwa/). SOAP snp software (http://soap.genomics.org.cn/) and SAM tools Pileup software (http://sourceforge.net/projects/samtools/) were used to detect single nucleotide variants (SNPs) and small insertions and deletions. Variants were annotated by ANNOVAR software, which is freely available at http://www.openbioinformatics.org/annovar/-. Variants were interpreted according to the American College of Medical Genetics and Genomics (ACMG) recommended standard.[14, 15]

2.2.2. Sanger sequencing. To validate true positive novel mutations identified by NGS, Sanger sequencing was performed to determine the presence or absence of this variant in the proband, most of other affected family members, a part of unaffected family members (III-11; III-14; III-15; III-23; III-31; IV-2; IV-10; IV-14; V-3; V-9; V-10; V-37; V-38; V-42; V-64; V-72; V-73; V-101; VI-17; VI-20; VI-21; VI-24) and 50 unrelated healthy controls.

The specific PCR primers (forward primer 5'-ACCTGGGA-CAGAGGACTCGC-3', reverse primer 5'- TGGAGGGTCTCGTACGTAGT-5') were used for the amplification of target gene site based on the reference sequences of human genome from GenBank in NCBI (NM_000142.4). PCR cycling was performed on a DNA thermal cycler (Gene Amp 9700, Perkin-Elmer, USA) with 2 x Hotstar Taq PCR Mastermix kit (Tiangen Biotech Beijing Co. LTD., China). In a 50 µL reaction mix, 300 ng of genomic DNA were used with 2.0 µL of each primer (10 µmol/L), and 25 µL of 2 x PCR Mastermix. Genomic DNA was first denatured at 94°C for 3 min, followed by 31 cycles of 94°C for 35 s, 60°C for 35 s, and 72°C for 30 s. The PCR products were extended at 72°C for 5 min. The products were gel-purified with an agarose gel DNA purification kit (Tiangen Biotech Beijing Co. LTD., China), and the purified PCR products were sequenced using the forward and reverse primers. Automated sequencing was performed at both ends on an ABI 377 automatic sequencer.

2.2.3. In silico analysis. Deletious effects of the detected novel mutation on protein function were predicted using 2 web-based tools: Sorting Intolent from Tolerant (SIFT) and Polymorphism Phenotyping v2 (PolyPhen-2). SIFT (http://sift.bi.a-star.edu.sg/) is a sequences homology-based tool which presumes that the important amino acids are conserved in the protein family. Its results were expressed as SIFT scores which were classified as damaging (0.00–0.05), potentially damaging (0.051–0.10), borderline (0.101–0.20), or tolerant (0.201–1.00). PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) is a web-based tool which predicts possible impact of an amino acid substitution on the structure and function of a human protein using straightforward physical and comparative considerations.[16] Three possible outcomes of mutations were predicted by PolyPhen-2: probably damaging, possibly damaging or benign according to the score ranging from 0 to 1.

Three-dimensional structure modeling of wild and mutant FGFR3 was built by using the FR-t5-M[17] and CIS-RR.[18] The molecular docking analysis was performed with ZDOCK 3.0.2 (http://zdock.umassmed.edu/) to examine ligand-binding affinity between FGFR3 (wild and mutant) and its main ligand, fibroblast growth factor 9 (FGF9).[19] The top 10 complex models were selected as candidates. The binding affinity was evaluated by ZDOCK score. PyMol (http://www.pymol.org/) was used to draw the structure models.

3. Results

3.1. Clinical data

The proband was a disproportionate dwarf with short-limbs, brachydactyly and slight genu varum (Fig. 2A) but she did not have tranquil hands. Her face is normal and she is of normal intelligence. Current weight was 23.1 kg (–0.3 SD), height 116.0 cm (–2.1 SD), her upper to lower segment ratio 1.32 and head circumference 52.2 cm. Her serum concentrations of alkaline phosphatase, insulin-like growth factor 1 (IGF-1), IGF-binding proteins, and thyroid hormone were normal.

Radiological studies revealed short limbs with slight brachydactyly, caudal narrowing of the interpediculate distance of the lumbar spine (Fig. 2B), short iliac bones and short femoral necks (Fig. 2C), short stubby tibias, mildly increased fibular lengths and genu varum. Her clinical and radiologic findings were consistent with clinico-radiologic criteria for HCH.[18]

The clinical features of living affected members with HCH in this large Chinese Han family are presented in the Table 1.

3.2. Mutation detection

In this study, 8 variants in FGFR3 gene were detected by NGS. We then excluded those variants with an allele frequency more than 5% in the dbSNP data-base, 1000 human genome dataset, exome aggregation consortium (ExAC) and genome aggregation database (gnomAD). According to the detailed filtering criteria and analysis pipeline published before,[20] a C to T transition at nucleotide position 1052 in the cDNA of FGFR3 gene was identified in both the proband and her father. C1052T mutation was then confirmed by Sanger sequencing (Fig. 3A). This heterozygous mutation resides in the extracellular Ig domain III of FGFR3 (Fig. 3B) and results in the substitution of serine by phenylalanine (S3351F). It co-segregates with other affected individuals of the Chinese Han pedigree with HCH. No mutation at this site was found in 23 unaffected family members detected or in 50 unrelated healthy controls. According to the HGMD (http://www.hgmd.cf.ac.uk/docs/login. html), this heterozygous mutation is novel.

Our homology analysis of the S331F site in different animal species indicated that the position of this mutation was highly conserved (Fig. 3C), which supported the possibility that this mutation was pathogenic.

3.3. In silico analysis

The results of SIFT and PolyPhen-2 analysis of this mutation provided further evidence that the mutation is the cause of the clinical phenotype. This mutation is predicted to be deleterious with a SIFT score of 0.000 and possibly damaging with a PolyPhen-2 score of 0.935.

Three-dimensional structure of FGFR3 (S331F) was created by replacing S331 with F331. F331 has an influence on the surface of FGFR3 relative to S331, which causes this residue site to change...
from the sunk to the raised (Fig. 3D, E). The molecular docking was successfully completed between FGFR3 (the wild and the mutant) and its ligand FGF-9 respectively (Fig. 3F, G). Because the mutation S351F changes the FGFR3 interface, the mutant FGFR3 displayed stronger binding to FGF-9 compared to the wild FGFR3, which is further supported by TOP10 ZDock Score (F351 vs S351, 1244.6 ± 64.2 vs 1115.8 ± 37.3, P < .01).

4. Discussion

HCH is characterized by clinical manifestations with the average height of adults—146 cm in males and 138 cm in females. The diagnosis of HCH is suspected on clinical grounds of short stature, a height prediction inappropriate for the family, and in some cases by diminution of the pubertal growth spurt and confirmed by several distinctive radiologic findings, such as brachydactyly, metaphyseal flaring, shortening of the pedicles of the vertebrae, lack of increase in interpedicuilar distance between lumbar vertebrae L1 and L5, short iliac bones and short femoral necks, and short tubular bones.[5,21–23]

However, the diagnosis of HCH is hampered sometimes because severe forms of HCH may overlap clinically with ACH, especially in younger children, and even some HCH patients may be diagnosed with idiopathic short stature because of its less severe skeletal features than patients with ACH. In the present study, a very large HCH family with 53 affected members is reported. All patients have typical features of the HCH. There is small variable expressivity within this family, for example, most of them have genu varum, but small number of them doesn’t have this symptom. All affected members lack a trident hand and abnormal face that may help distinguish HCH from ACH. The radiologic findings of the proband and some affected family members show short limbs with slight brachydactyly, narrowing of interpedicuilar distance between lumbar vertebrae L1 and L5, short iliac bones and short femoral necks, which are consistent with radiologic criteria for HCH.

Human FGFR3 gene was identified as the HCH gene in 1995.[24,25] This gene consists of 19 exons and 18 introns,[26] and encodes an 840-residue FGFR3, a trans-membrane receptor that belongs to FGFR superfamily (FGFRs) including FGFR1 to FGFR4.[27,28] FGFRs are responsible for mediating the transmission of the intracellular signaling cascade generated when they bind to the fibroblast growth factors (FGFs), including 18 members (FGF1–FGF10 and FGF16–FGF23).[7] The formation of the dimer FGF-FGFR induces receptor dimerization, leading to auto- and transphosphorylation, followed by controlled activation of specific signal transduction pathways and expression of selected target genes in developmental pathways, which seems to have a specific role as negative regulator of bone growth.[29–31] FGFR-3 deficient mice had a marked increase in the length of the vertebral column and long bones as a result of enhanced and prolonged bone growth. Indeed, the known FGFR3 gene mutations related to HCH are gain of function mutations with ligand-independent activation of the receptor that results in decreased inhibition of endochondral ossification.[11]

Up to date, at least thirty mutations have been reported to be related to HCH according to HGMD, PubMed, Embase, and Web of Science. All mutations that were hitherto reported were listed in Table 2. About 60% of cases of HCH are due to mutations in the intracellular FGFR3-tyrosine kinase domain, such as N540K, I538V, though mutations may present in every domain of FGFR3.[21,40,41] In this research, by using NGS and Sanger sequencing, we identified a novel missense mutation (C1052T) resulting in S351F substitution in the extracellular domain Ig III in a very large Chinese family consisting of 53 affected individuals with classic HCH phenotypes.
After searching the SNP database and the human gene mutation database, we found that c.1052C→T [p.S351F] was absent from these databases. We demonstrate that this family carries a novel heterozygous mutation based on the following evidences. First, the mutation is not present in the unaffected family members or in 50 unrelated healthy controls. Second, the mutation resides in a highly conserved region when comparing different animal species. Third, prediction of functional consequence shows that this mutation is deleterious with a SIFT score of 0.000 and possibly damaging with a Poly Phen-2 score of 0.935.

Thirty mutations reported previously affect different aspects of FGFR3 function. The common denominator among them was thought to be constitutive, ligand-independent activation of the receptor, leading to impaired chondrocyte differentiation.[30] In this study, the S351F mutation is in the extracellular, ligand-binding domain and outside the intracellular domain TK1 or TK2 of FGFR3, without altering significantly 3-dimensional structure of TK1 or TK2 or disrupting normal folding of the IgIII loop. Nevertheless, this gain of function mutation displays an increase in ligand-binding affinity, therefore it may serve as a model to investigate ligand-dependent activity of FGF-FGFR complex.

Thus far, the phenotype/genotype correlation in patients with HCH is poor, though clinical heterogeneity has been associated with either different mutations in the FGFR3 gene or with cases unlinked to the FGFR3 gene. Ramaswami et al reported that

| Subject | Gender | Age, yr | Height, cm | Intelligence | Face | Macrocephaly | Shortened limbs | Genu varum | S351F mutation |
|---------|--------|---------|------------|-------------|------|--------------|----------------|------------|----------------|
| II.7    | M      | 83      | 150        | Norm        | Y    | Y            | Y              | Y          | Not tested     |
| II.10   | F      | 81      | 148        | Norm        | Y    | Y            | Y              | Y          | Not tested     |
| II.21   | M      | 85      | 150        | Norm        | Y    | Y            | Y              | Y          | Not tested     |
| II.25   | M      | 74      | 150        | Norm        | Y    | Y            | Y              | Y          | Not tested     |
| II.27   | M      | 74      | 155        | Norm        | Y    | Y            | Y              | N          | Y              |
| II.30   | F      | 72      | 152        | Norm        | Y    | Y            | Y              | Y          | Not tested     |
| II.34   | F      | 67      | 142        | Norm        | Y    | Y            | Y              | N          | Y              |
| II.36   | F      | 65      | 145        | Norm        | Y    | Y            | Y              | N          | Y              |
| N.6     | F      | 55      | 150        | Norm        | Y    | Y            | Y              | Y          | Y              |
| N.13    | F      | 55      | 147        | Norm        | Y    | Y            | Y              | Y          | Not tested     |
| N.17    | F      | 51      | 149        | Norm        | Y    | Y            | Y              | Y          | Not tested     |
| N.18    | M      | 48      | 145        | Norm        | Y    | Y            | Y              | N          | Y              |
| N.21    | F      | 46      | 147        | Norm        | Y    | Y            | Y              | Y          | Not tested     |
| N.26    | F      | 46      | 145        | Norm        | Y    | Y            | Y              | Y          | Not tested     |
| N.36    | F      | 49      | 146        | Norm        | Y    | Y            | Y              | Y          | Not tested     |
| N.37    | M      | 47      | 153        | Norm        | Y    | Y            | Y              | Y          | Not tested     |
| N.40    | F      | 45      | 149        | Norm        | Y    | Y            | Y              | Y          | Y              |
| N.69    | F      | 52      | 150        | Norm        | Y    | Y            | Y              | Y          | Not tested     |
| N.70    | M      | 50      | 156        | Norm        | Y    | Y            | Y              | Y          | Y              |
| N.72    | M      | 48      | 155        | Norm        | Y    | Y            | Y              | N          | Y              |
| N.75    | F      | 46      | 149        | Norm        | Y    | Y            | Y              | Y          | Y              |
| N.84    | M      | 48      | 153        | Norm        | Y    | Y            | Y              | Y          | Not tested     |
| N.87    | F      | 46      | 147        | Norm        | Y    | Y            | Y              | Y          | Y              |
| N.90    | M      | 43      | 150        | Norm        | Y    | Y            | Y              | N          | N              |
| N.93    | F      | 41      | 147        | Norm        | Y    | Y            | Y              | Y          | Y              |
| N.94    | M      | 38      | 150        | Norm        | Y    | Y            | Y              | Y          | Not tested     |
| N.100   | F      | 41      | 149        | Norm        | Y    | Y            | Y              | Y          | Y              |
| N.108   | F      | 34      | 146        | Norm        | Y    | Y            | Y              | Y          | Not tested     |
| V.7     | F      | 22      | 148        | Norm        | Y    | Y            | Y              | Y          | Y              |
| V.16    | F      | 32      | 146        | Norm        | Y    | Y            | Y              | Y          | Y              |
| V.17    | M      | 29      | 151        | Norm        | Y    | Y            | Y              | Y          | Not tested     |
| V.20    | F      | 27      | 146        | Norm        | Y    | Y            | Y              | Y          | Not tested     |
| V.35    | M      | 29      | 150        | Norm        | Y    | Y            | Y              | Y          | Y              |
| V.55    | F      | 22      | 147        | Norm        | Y    | Y            | Y              | Y          | Y              |
| V.56    | F      | 23      | 150        | Norm        | F    | Y            | Y              | Y          | Y              |
| V.67    | M      | 19      | 151        | Norm        | F    | Y            | Y              | Y          | Not tested     |
| V.84    | F      | 19      | 143        | Norm        | Y    | Y            | Y              | Y          | Y              |
| V.87    | F      | 23      | 143        | Norm        | Y    | Y            | Y              | Y          | Y              |
| V.98    | F      | 19      | 143        | Norm        | Y    | Y            | Y              | Y          | Y              |
| V.99    | M      | 20      | 146        | Norm        | Y    | Y            | Y              | Y          | Y              |
| V.102   | M      | 12      | 135 (−2.3SD) | Norm      | Y    | Y            | Y              | N          | Y              |
| VI.3    | M      | 13      | 140 (−2.5SD) | Norm      | Y    | Y            | Y              | Y          | Not tested     |
| VI.4    | F      | 11      | 132 (−2.1SD) | Norm      | Y    | Y            | Y              | N          | Y              |
| VI.5    | F      | 7yr 8mo | 116 (−2.1SD) | Norm      | Y    | Y            | Y              | Y          | Y              |
| VI.16   | M      | 5yr 9mo | 106 (−2.2SD) | Norm      | Y    | Y            | Y              | Y          | Y              |
| VI.22   | M      | 2yr 1mo | 83 (−2.0SD) | Norm      | Y    | Y            | Y              | N          | Y              |

M=male, F=female, Norm=normal, Y=yes, N=no, N/A=not applicable, yr=year, mo=month.

* Subjects selected for next-generation sequencing.
HCH children with heterozygous N540K mutation were more severely affected than those without N540K mutation, and the former had a higher and larger forehead and shorter hands than the latter. Some studies showed that individuals with the FGFR3 N540K mutation may have an increased incidence of mild to moderate intellectual disability or learning disabilities. However, Song et al (1999) suggested that the clinical findings were similar in 2 groups of HCH with or without FGFR3 mutations, only the radiological findings of mesomelia of upper and lower limbs and, L/L4 ratio in anterior–posterior and lateral view were more typical in HCH with FGFR3 mutations than in HCH without FGFR3 mutations. De Rosa et al described a 16-month-old male with N540K homozygous mutation in the FGFR3 gene who showed a more severe phenotype than the usual heterozygous HCH, which was even shorter than the heterozygous ACH. In our research, the main symptom (short stature) was mild in this HCH family with height of adults—145~159 cm in males, 142~152 cm in females and children, −2.0~−2.5 SD in boys, −2.1SD in a girl, whether that arises from enhanced ligand-binding affinity or not should be further investigated.

5. Conclusion

In summary, we present evidence that S351F mutation represents a novel FGFR3 mutation in a large Chinese family with HCH. This gain of function mutation does not alter significantly 3-dimensional structure of TK1 or TK2 or disrupting normal folding of the IgIII loop. Nevertheless, this unique mutation
The family.

dependent activation of the receptor and genetic counseling of and have important implications for investigating ligand-dependent activity of FGFR-FGFR complex. Our data extend the mutation spectrum of FGFR3 gene and have important implications for investigating ligand-dependent activation of the receptor and genetic counseling of the family.

Acknowledgments

The authors thank the patients and their family members for their cooperation in this study. The authors are grateful to Dr Carl E Stafstrom and Dr. Li-rong Shao, professor and assistant professor respectively at Department of Neurology, School of Medicine, Johns Hopkins University, USA, for proofreading the manuscript.

Author contributions

Data curation: Guixiang Yao, Guangxin Wang.
Formal analysis: Guixiang Yao, Guangxin Wang.
Funding acquisition: Guohai Su.
Investigation: Guixiang Yao, Guangxin Wang.
Project administration: Guixiang Yao, Dawei Wang, Guohai Su.
Resources: Guangxin Wang, Dawei Wang.
Software: Dawei Wang.
Supervision: Guohai Su.
Writing – original draft: Guixiang Yao, Guangxin Wang.
Writing – review & editing: Guohai Su.

Table 2

The summary of previously reported FGFR3 mutations causing HCH.

| Author, year | Mutations in FGFR3 | Codon change | Codon number | Mutation types | References |
|--------------|---------------------|--------------|--------------|---------------|------------|
| Song, et al, 2012 | c.1030G>T(p.S343*) | GGG-CGG | 343 | missense | [8] |
| Heuertz, et al, 2006 | c.251C>T(p.S84L) | TGC-TTG | 84 | missense | [32] |
| Song, et al, 2012 | c.344A>T(p.Q115*); c.344G>A(p.R115*) | CAG-CTG | 115 | missense | [8] |
| Heuertz, et al, 2006 | c.598C>T(p.R200*) | CGC-TGC | 200 | missense | [32] |
| Heuertz, et al, 2006 | c.784A>C(p.N262*) | AAC-CAC | 262 | missense | [8] |
| Song, et al, 2012 | c.791C>T(p.R264*) | ACG-ATG | 264 | missense | [32] |
| Heuertz, et al, 2006 | c.802G>T(p.G268*) | GCC-TGC | 268 | missense | [3] |
| Takahashi, et al, 2018 | c.805A>T(p.G269*) | AGC-TGC | 269 | missense | [3] |
| Heuertz, et al, 2006 | c.833A>G(p.Y278*) | TAC-TGC | 278 | missense | [32] |
| Bajaj, et al, 2008 | c.835A>T(p.S279*) | AGT-TAG | 279 | missense | [33] |
| Bajaj, et al, 2008 | c.883G>T(p.G295*) | GCC-TGC | 295 | missense | [33] |
| Saito, et al, 2012 | c.970C>G(p. L324*) | GTA-GTA | 324 | missense | [14] |
| Nagahara, et al, 2016 | c.971C>G(p. L324*) | GTA-GTA | 324 | missense | [6] |
| Winterpacht, et al, 2000 | c.983A>G(p. R328*) | AAG-AGA | 328 | missense | [31] |
| Wang, et al, 2013 | c.1024G>T(p.S342*) | GCC-TGC | 342 | missense | [22] |
| Bajaj, et al, 2008 | c.1052C>T(p.R348*) | AAG-AGA | 348 | missense | [33] |
| Bajaj, et al, 2008 | c.1078G>A(p. E360*) | GAG-AAG | 360 | missense | [33] |
| Prinos, et al, 1995 | c.1138G>A(p. R380*) | GAG-AGA | 380 | missense | [24] |
| Almeida, et al, 2009 | c.1138G>A(p. R380*) | GAG-AGA | 380 | missense | [15] |
| Heuertz, et al, 2006 | c.1142T>A(p.V381*) | GAT-GAT | 381 | missense | [32] |
| Chen, et al, 2018 | c.1145G>A(p. R382*) | GCC-GAC | 382 | missense | [6] |
| Bajaj, et al, 2008 | c.1454A>G(p. Q485*) | CAT-CTG | 485 | missense | [33] |
| Grigelioniene, et al, 1998 | c.1611G>T(p.U537*) | ATC-TGC | 537 | missense | [36] |
| Prinos, et al, 1995 | c.1620C>G(p. Q540*) | AAC-AAC | 540 | missense | [24] |
| Prinos, et al, 1995 | c.1620C>G(p. Q540*) | AAC-AAC | 540 | missense | [24] |
| Deutz-Terlouw, et al, 1998 | c.1619A>G(p. Q540L) | AAC-ACC | 540 | missense | [24] |
| Mortier, et al, 2000 | c.1619A>G(p. Q540L) | AAC-ACC | 540 | missense | [24] |
| Bellus, et al, 2000 | c.1650G>C(p. S550*) | AAG-GG | 550 | missense | [36] |
| Bellus, et al, 2000 | c.1650G>C(p. S550*) | AAG-GG | 550 | missense | [36] |
| Bellus, et al, 2000 | c.1948A>G(p. K650*) | AAG-CAG | 650 | missense | [36] |
| Bellus, et al, 2000 | c.1948A>G(p. K650*) | AAG-CAG | 650 | missense | [36] |

FGFR3 = fibroblast growth factor receptor 3, HCH = hypochondroplasia.

References

[1] Bonafe L, Cormier-Daire V, Hall C, et al. Nosology and classification of genetic skeletal disorders: 2015 revision. Am J Med Genet A 2015;167A:2869–92.
[2] Saito T, Nagasaki K, Nishimura G, et al. Criteria for radiologic diagnosis of hypochondroplasia in neonates. Pediatr Radiol 2016;46:513–8.
[3] Takahashi I, Kondo D, Oyama C, et al. A novel S269C mutation in fibroblast growth factor receptor 3 in a Japanese child with hypochondroplasia. Hum Genom Var 2018;5:1–5.
[4] Miyazaki M, Kanezaki S, Notami N, et al. Spinal deformity and lateral lumbar interbody fusion for thoracolumbar kyphosis in an adult with achondroplasia: A case report. Medicine (Baltimore) 2017;96:1–4.
[5] Nagahara K, Harada Y, Futami T, et al. A Japanese familial case of hypochondroplasia with a novel mutation in FGFR3. Clin Pediatr Endocrinol 2016;25:103–6.
[6] Chen J, Yang J, Zhao S, et al. Identification of a novel mutation in the HCH gene in a Chinese family with hypochondroplasia. Gene 2018;641:355–60.
[7] Sargar KM, Singh AK, Kao SC. Imaging of skeletal disorders caused by fibroblast growth factor receptor gene mutations. Radiographics 2017;37:1813–30.
[8] Song SH, Bakse GC, Agashe MV, et al. New proposed clinico-radiologic and molecular criteria in hypochondroplasia: FGFR3 gene mutations are not the only cause of hypochondroplasia. Am J Med Genet A 2012;158A:2456–62.
[9] Cohen MM Jr. Achondroplasia, hypochondroplasia and thanatophoric dysplasia: clinically related skeletal dysplasias that are also related at the molecular level. Int J Oral Maxillofac Surg 1998;27:451–5.
[10] Schlesinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211–25.
[11] De Sanctis V, Baldi M, Marsciani A, et al. ASN540SER mutation is not the only cause of hypochondroplasia. Am J Med Genet A 2013;167A:2869–92.
[12] Fu X, Yang H, Jiao H, et al. Novel copy number variation of POMGNT1 associated with muscle-eye-brain disease detected by next-generation sequencing. Sci Rep 2017;7:1–9.

[13] Talebi F, Ghanbari Mardasi F, Mohammadi Asl J, et al. Identification of a novel missense mutation in FGFR3 gene in an Iranian family with LADD syndrome by next-generation sequencing. Int J Pediatr Otorhinolaryngol 2017;97:192–6.

[14] Richards CS, Bale S, Bellissimo DB, et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med 2008;10:294–300.

[15] Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med 2015;17:405–24.

[16] Desai M, Chouthai JB. Computational analysis for the determination of deleterious nsSNPs in human MTHFD1 gene. Comput Biol Chem 2017;70:7–14.

[17] Dai W, Song T, Wang X, et al. Improvement in low-homology template-based modeling by employing a model evaluation method with focus on topology. PLoS One 2014;9:1–9.

[18] Cao Y, Song L, Miao Z, et al. Improved side-chain modeling by coupling clash-detection guided iterative search with rotamer relaxation. Bioinformatics 2011;27:785–90.

[19] Ornitz DM. FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev 2005;16:205–13.

[20] Wei X, Ju X, Yi X, et al. Identification of sequence variants in genetic disease-causing genes using targeted next-generation sequencing. PLoS One 2011;6:1–10.

[21] Ramaswami U, Rumsby G, Hindmarsh PC, et al. Genotype and phenotype in hypochondroplasia. J Pediatr 1998;133:99–102.

[22] Wang H, Sun Y, Wu W, et al. A novel missense mutation of FGFR3 in a Chinese female and her fetus with Hypochondroplasia by next-generation sequencing. Clin Chim Acta 2013;423:62–5.

[23] Kotysova L, Mattosova S, Chandoga J. Improvement of molecular-genetic diagnostics of the most common skeletal dysplasias. Bratisl Lek Listy 2015;116:465–8.

[24] Prin Prinos os P, Costa T, Sommer A, et al. A common FGFR3 gene mutation in hypochondroplasia. Hum Mol Genet 1995;4:2097–101.

[25] Bellus GA, McIntosh I, Smith EA, et al. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat Genet 1995;10:357–9.

[26] Gomes MES, Kanazawa TY, Riha FR, et al. Novel and Recurrent Mutations in the FGFR3 Gene and Double Heterozygosity Cases in a Cohort of Brazilian Patients with Skeletal Dysplasia. Mol Syndromol 2018;9:92–9.

[27] Teven CM, Farina EM, Rivas J, et al. Fibroblast growth factor (FGF) signaling in development and skeletal diseases. Genes Dis 2014;1:199–213.

[28] Fu W, Chen L, Wang Z, et al. Theoretical studies on FGFR isoform selectivity of FGFR1/FGFR4 inhibitors by molecular dynamics simulations and free energy calculations. Phys Chem Chem Phys 2017;19:3649–59.

[29] Perez-Castro AV, Wilson J, Altsherr MR. Genomic organization of the human fibroblast growth factor receptor 3 (FGFR3) gene and comparative sequence analysis with the mouse Fgfr3 gene. Genomics 1997;41:10–6.

[30] Adar R, Monsonego-Ornan E, David P, et al. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization. J Bone Miner Res 2002;17:860–8.

[31] Winterpacht A, Hilbert K, Stelzer C, et al. A novel mutation in FGFR3 disrupts a putative N-glycosylation site and results in hypochondroplasia. Physiol Genomics 2002;9:9–12.

[32] Heuertz S, Le Merret M, Zabel B, et al. Novel FGFR3 mutations creating cysteine residues in the extracellular domain of the receptor cause achondroplasia or severe forms of hypochondroplasia. Eur J Hum Genet 2006;14:1240–7.

[33] Bouaj G, Leges-Mallet L, Finisgori G, et al. Achondroplasia. Best Prac Res Clin Rheumatol 2008;22:3–18.

[34] Saito T, Nagasaki K, Nishimura G, et al. Radiological clues to the early diagnosis of hypochondroplasia in the neonatal period: report of two patients. Am J Med Genet A 2012;158A:630–4.

[35] Almeida MR, Campos-Xavier AR, Medeira A, et al. Clinical and molecular diagnosis of the skeletal dysplasias associated with mutations in the gene encoding Fibroblast Growth Factor Receptor 3 (FGFR3) in Portugal. Clin Genet 2009;75:150–6.

[36] Grigelioniene G, Hagenius L, Eklof O, et al. A novel missense mutation Ile538Val in the fibroblast growth factor receptor 3 gene in hypochondroplasia. J Pediatr Orthop 2011;31:21–5.

[37] Deutz-Terlouw PP, Losekoot M, Aalbers CM, et al. Asn540Thr substitution in the fibroblast growth factor receptor 3 tyrosine kinase domain causing hypochondroplasia. Hum Mutat 2006;27:882–8.

[38] Mortier G, Nuyttenck L, Craen M, et al. Clinical and radiographic features of a family with hypochondroplasia owing to a novel Asn540Ser mutation in the fibroblast growth factor receptor 3 gene. J Med Genet 2008;45:220–4.

[39] Bellus GA, Spector EB, Spenser PW, et al. Distinct missense mutations of the Fgfr3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. Am J Hum Genet 2000;67:1411–21.

[40] Shin YL, Choi JH, Kim GH, et al. Comparison of clinical, radiological and molecular findings in Korean infants and children with achondroplasia and hypochondroplasia. J Pediatr Endocrinol Metab 2005;18:999–1005.

[41] Katsumata N, Nakazawa M, Miyokawa N, et al. Analysis of the FGFR3 gene in Japanese patients with achondroplasia and hypochondroplasia. Endocr J 2000;47:5121–4.

[42] Korkmaz HA, Hazan F, Dudarar C, et al. Hypochondroplasia in a child with 1620C>G (Asn540Lys) mutation in FGFR3. J Clin Res Pediatr Endocrinol 2012;4:220–2.

[43] De Rosa ML, Fano V, Araoz HV, et al. Homozygous N540K hypochondroplasia-first report: radiological and clinical features. Am J Med Genet A 2014;164A:1784–8.